Skip to main content
Search
Search
    Quick Search anywhere
    Quick search in Citations
Advanced Search
Skip main navigationClose Drawer MenuOpen Drawer Menu
Previous article
Next article
Original communication

Osteoprotegerin concentration is associated with the presence and severity of peripheral arterial disease in type 2 diabetes mellitus

Published Online:January 09, 2018https://doi.org/10.1024/0301-1526/a000682

Abstract

Abstract.Background: Osteoprotegerin plays a role in the development of several bone diseases. In addition, osteoprotegerin may contribute to the development of vascular disease. Little is known about the association between serum osteoprotegerin levels and the presence or severity of peripheral arterial disease (PAD). The aim of this study was to examine the association between serum osteoprotegerin levels and both the presence as well as the severity of lower extremity arterial disease in patients with type 2 diabetes (T2DM). Patients and methods: The study included 165 consecutive patients with T2DM (57 % males, mean age 65.0 ± 0.7 years). PAD was diagnosed by measurement of the toe-brachial index (TBI). Serum osteoprotegerin was measured using ELISA. Results: The mean osteoprotegerin level was significantly higher in patients with PAD in comparison to patients without PAD (18.2 ± 1.0 vs. 13.1 ± 2.0 pmol/L, p = 0.014). Significant univariate correlations between TBI and osteoprotegerin level (r = –0.308; p < 0.001), age, body mass index, and HDL cholesterol were observed. In the multivariate linear regression analysis, serum osteoprotegerin (β = –0.005; p = 0.020), higher age, and male gender were significant predictors of TBI. When 25(OH) vitamin D was introduced into the mentioned model, OPG was no longer a significant predictor of TBI and was replaced in the model with vitamin D (β = 0.009, p = 0.001). This finding suggests a role of OPG as a mediator of the effects of 25(OH) vitamin D. Conclusions: Serum osteoprotegerin level is significantly associated with both the presence and severity of PAD in patients with T2D. Osteoprotegerin might be a biomarker for the presence of atherosclerotic disease in patients with T2DM.

Literature

  • Biscetti F, Porreca CF, Bertucci F, Straface G, Santoliquido A & Tondi P, et al. TNFRSF11B gene polymorphisms increased risk of peripheral arterial occlusive disease and critical limb ischemia in patients with type 2 diabetes. Acta Diabetol. 2014;51:1025–32. First citation in articleCrossref Medline, Google Scholar

  • Esteghamati A, Aflatoonian M, Rad MV, Mazaheri T, Mousavizadeh M & Nakhjavani M, et al. Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes. Arch Cardiovasc Dis. 2015;108:412–9. First citation in articleCrossref Medline, Google Scholar

  • O´Sullivan EP, Ashley DT, Davenport C, Kelly J, Devlin N & Crowley R, et al. Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status. Thromb Res. 2010;126:e423–7. First citation in articleCrossref Medline, Google Scholar

  • Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M & Mayr A, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109:2175–80. First citation in articleCrossref Medline, Google Scholar

  • Ziegler S, Kudlacek S, Luger A & Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis. 2005;182:175–80. First citation in articleCrossref Medline, Google Scholar

  • Golledge J, McCann M, Mangan S, Lam A & Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004;35:1636–41. First citation in articleCrossref Medline, Google Scholar

  • Straface G, Biscetti F, Pitocco D, Bertoletti G, Misuraca M & Vincenzoni C, et al. Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability. Stroke. 2011;42:3022–8. First citation in articleCrossref Medline, Google Scholar

  • Sandberg WJ, Yndestad A, Øie E, Smith C & Ueland T. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol. 2006;26:857–63. First citation in articleCrossref Medline, Google Scholar

  • Crisafulli A, Micari A, Altavilla D, Saporito F & Sardella A. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond). 2005;109:389–95. First citation in articleCrossref Medline, Google Scholar

  • Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B & Froland SS, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005;111:2461–8. First citation in articleCrossref Medline, Google Scholar

  • Browner WS, Lui LY & Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol MeTab. 2001;86:631–7. First citation in articleMedline, Google Scholar

  • Poulsen MK, Nybo M, Dahl J, Hosbond S, Poulsen TS & Johansen A, et al. Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus. Cardiovasc Diabetol. 2011;10:76. First citation in articleCrossref Medline, Google Scholar

  • Niu Y, Zhang W, Zhen Y, Li X, Wen J & Wang S, et al. Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes. BMC Cardiovasc Dis. 2015;15:86. First citation in articleCrossref Medline, Google Scholar

  • Frick M, Baumann F, Sick B, Wilkinson IB, Amann-Vesti B & Husmann M. Sensitivities of in vivo markers of arterial organ damage in patients with peripheral atherosclerosis. Vasa. 2018;47:30–35. First citation in articleLink, Google Scholar

  • Ye Z, Ali Z, Klee GG, Mosley Jr TH & Kullo IJ. Associations of candidate biomarkers of vascular disease with the ankle-brachial index and peripheral arterial disease. Am J Hypert. 2013;26:495–502. First citation in articleCrossref Medline, Google Scholar

  • Suominen V, Rantanen T, Venermo M, Saarinen J & Salenius J. Prevalence and risk factors of PAD among patients with elevated ABI. J Vasc Endovasc Surg. 2008;35:709–14. First citation in articleCrossref Medline, Google Scholar

  • Park SC, Choi CY, Ha YI & Yang HE. Utility of the toe-brachial index for diagnosis of peripheral artery disease. Arch Plast Surg. 2012;39:227–31. First citation in articleCrossref Medline, Google Scholar

  • Hyun S, Forbang NI, Allison MA, Denenberg JO, Criqui MH & Ix JH. Ankle-brachial index, toe-brachial index, and cardiovascular mortality in persons with and without diabetes mellitus. J Vasc Surg. 2014;60:390–5. First citation in articleCrossref Medline, Google Scholar

  • Norgren L, Hiatt WR & Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33:S1–75. First citation in articleCrossref Medline, Google Scholar

  • Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA & Findeiss LK, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 Guideline). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58:2020–45. First citation in articleMedline, Google Scholar

  • Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J & Schett G. The osteoprotegerin /RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther. 2006;4:801–11. First citation in articleCrossref Medline, Google Scholar

  • Zhou S, Fang X, Xin H, Li W, Qiu H & Guan S. Osteoprotegerin inhibits calcification of vascular smooth muscle cell via down regulation of the Notch1-RBP-Jκ/Msx2 signaling pathway. PLoS ONE. 2013;8:e68987. First citation in articleCrossref Medline, Google Scholar

  • Tousoulis D, Siasos G, Maniatis K, Oikonomou E, Kioufis S & Zaromitidou M, et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol. 2013;167:1924–8. First citation in articleCrossref Medline, Google Scholar

  • Rogers A & Eastell R. REVIEW: Circulating osteoprotegerin and receptor activator for nuclear factor-κB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005;90:6323–31. First citation in articleCrossref Medline, Google Scholar

  • Pleskovič A, Mankoč Ramuš S, Jenko Pražnikar Z , Šantl Letonja M, Cokan Vujkovac A & Gazdikova K, et al. Polymorphism rs2073618 of the osteoprotegerin gene as a potential marker of subclinical carotid atherosclerosis in Caucasians with type 2 diabetes mellitus. Vasa. 2017;46:1–8. First citation in articleGoogle Scholar

  • Marso SP & Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47:921–9. First citation in articleCrossref Medline, Google Scholar